ICER Evidence Report for Inclisiran Released

February 8, 2021

Inclisiran by Novartis may be priced lower than other drugs targeting LDL cholesterol. Now that ICER has released its pricing report, the next question is: what will Novartis do?  that keeping inclisiran cost-effective is a serious consideration.

“In our recent Evidence Report, ICER concluded that inclisiran (Novartis) can substantially lower LDL cholesterol, and we recommended a health-benefit price benchmark price of between $3,600 and $6,000 per year. Inclisiran’s cholesterol-lowering ability is similar to that demonstrated by the PCSK9 inhibitors Praluent and Repatha — two treatments that were launched with annual prices above $14,000, faced significant payer pushback for multiple years, and eventually saw price reductions toward ICER’s recommended range.” Read more about the ICER report here.

(Source: Angus Liu, Fierce Pharma, 1/29/21)

Share This Story!